Subtotal $0.00
Shop Now
Amycretin is an investigational weight-loss medicine from Novo Nordisk, the maker of Ozempic and Wegovy. It is a single molecule that activates two hormone receptors, GLP-1 and amylin, and it is being tested both as a weekly injection and as a daily tablet. Amycretin is not FDA-approved and cannot be bought; it is available only in clinical trials. In an early injection study published in The Lancet in 2025, people lost an average of 22% of their body weight over 36 weeks on one schedule, versus a small gain on placebo, but the study was small and many participants dropped out. A phase 3 obesity trial called AMAZE 1 started in February 2026.
Peptide Labs does not sell amycretin, any version of it or any prescription drug. Products sold online as “amycretin” or as a “research” version are not the investigational medicine. This article summarizes published trials, Novo Nordisk announcements and ClinicalTrials.gov records.
Key Takeaways
- Amycretin is a Novo Nordisk drug in development, not FDA-approved and not available outside trials.
- One molecule activates both the GLP-1 receptor and the amylin receptor.
- It is being tested as a once-weekly injection and as a once-daily tablet.
- Early injection study: up to 24.3% average weight loss at 36 weeks, in a small single-site trial.
- Type 2 diabetes phase 2: up to 14.5% weight loss with the injection and 10.1% with the tablet at 36 weeks.
- Digestive side effects were the most common; long-term safety is unknown.
What is amycretin?
Novo Nordisk describes amycretin as a unimolecular, long-acting GLP-1 and amylin receptor agonist, developed under the code NNC0487-0111. GLP-1 is the gut hormone behind semaglutide and the other drugs in our GLP-1 explainer. Amylin is a hormone made by the same pancreatic beta cells that make insulin, and it is released around meals. According to the label of pramlintide (Symlin), an amylin-like medicine approved for some people with diabetes in 2005, activating amylin receptors slows stomach emptying, reduces the after-meal rise in glucagon and increases fullness, leading to lower calorie intake.
Novo Nordisk has also developed CagriSema, which pairs semaglutide with a separate amylin analogue as two molecules. Amycretin puts both actions into one molecule, which is also what makes a tablet form possible to test. Our guide to the hormones that control hunger explains how GLP-1, amylin and others fit together.
Amycretin trial results so far
Three amycretin trials have reported results. All were funded by Novo Nordisk, and the first two were run at a single research clinic in San Antonio, Texas.
| Study | Form and length | Who took part | Average weight change |
|---|---|---|---|
| Phase 1 (Lancet 2025) | Daily tablet, 12 weeks in the longest part | 144 adults with overweight or obesity | About 13% loss on the highest step vs about 1% on placebo |
| Phase 1b/2a (Lancet 2025) | Weekly injection, up to 36 weeks | 125 adults aged 18 to 55 with overweight or obesity | 22.0% to 24.3% loss at 36 weeks vs a 1.1% loss to 1.9% gain on placebo |
| Phase 2 (company results, November 2025) | Weekly injection or daily tablet, 36 weeks | 448 adults with type 2 diabetes on metformin | Up to 14.5% loss (injection) and 10.1% (tablet) vs about 2.5% on placebo |
The injection study
In the phase 1b/2a study, 101 people received amycretin and 24 received placebo. Groups were stepped up to different maintenance levels over different lengths of time. The two groups that stayed on amycretin for 36 weeks lost an estimated 24.3% and 22.0% of body weight; a 28-week group lost 16.2%, and a 20-week group lost 9.7%. The authors noted that a large number of participants withdrew, many for reasons unrelated to side effects, which makes the averages less certain.
The tablet study
The first-in-human study tested oral amycretin in 144 adults, mostly over a few days or weeks to check safety and blood levels. In the longest part, 12 weeks of daily tablets, weight fell by about 13% on the highest step versus about 1% on placebo. Twelve weeks is far too short to show where weight loss would settle.
The type 2 diabetes study
In November 2025 Novo Nordisk announced headline results from a 36-week phase 2 amycretin trial in 448 people whose diabetes was not controlled on metformin, with or without an SGLT2 inhibitor. HbA1c fell by up to 1.8 percentage points with the injection and 1.5 points with the tablet. These were company-reported results, released before full peer-reviewed publication.
Cross-trial comparisons with approved drugs are unreliable because the studies differ in size, length and who took part. For the approved options, see weight loss in the main GLP-1 trials and our comparison of semaglutide and tirzepatide.
Side effects reported with amycretin
- Tablet study: 62% of the 144 participants reported at least one side effect, all mild or moderate, and they became more frequent at higher strengths. About half of all reported events were digestive. No deaths occurred.
- Injection study: digestive events were the most common, and most were mild to moderate and resolved by the end of the study. Almost everyone in both the amycretin and placebo groups reported some adverse event, which is common in closely monitored early trials.
- Diabetes study: Novo Nordisk reported that digestive events were the most common and mostly mild to moderate, consistent with other GLP-1 and amylin medicines.
These studies were small and short, so rare or long-term risks are unknown. Approved GLP-1 medicines carry warnings about pancreatitis, gallbladder problems and dehydration from vomiting or diarrhea; see our guide to side effects across the GLP-1 class.
Novo Nordisk amycretin phase 3 plans
In June 2025 Novo Nordisk said it would move both the injection and the tablet into phase 3 for weight management after discussions with regulators. The first large trial, AMAZE 1, is listed on ClinicalTrials.gov:
- Phase 3, about 1,150 adults with obesity, comparing a weekly amycretin injection with placebo.
- Both groups follow a reduced-calorie diet and increase physical activity.
- Started February 24, 2026, and still recruiting; main data collection is scheduled to finish in mid-2029.
After the diabetes results, Novo Nordisk also said it plans phase 3 trials in type 2 diabetes during 2026. Approval would require positive phase 3 results and an FDA review, so amycretin is years from pharmacies at the earliest, and may never reach them.
Can you get amycretin?
Only by enrolling in a clinical trial. ClinicalTrials.gov lists recruiting amycretin studies, and a study team decides who is eligible. Websites selling “amycretin” vials, tablets or “research peptides” are not offering the Novo Nordisk medicine. Such products are not reviewed by the FDA for identity, purity or sterility, and they are not approved for human use.
If you are interested in a trial, talk with your own doctor first. Trial participants may receive placebo, must attend regular study visits and follow the study’s safety rules, and can leave the study at any time. Our article on the legal status of peptides explains why unapproved products sold online carry real risks.
Frequently Asked Questions
Is amycretin FDA-approved?
No. Amycretin is investigational. As of October 2026 it is in phase 3 trials and is available only to people enrolled in those studies.
How does amycretin work?
It is one molecule that activates both the GLP-1 receptor and the amylin receptor. Both hormones slow stomach emptying and increase fullness, which lowers food intake.
How much weight did people lose in the amycretin trial?
In the early injection study, the 36-week groups lost about 22% to 24% of body weight on average. In the diabetes trial, losses reached 14.5% with the injection and 10.1% with the tablet.
Is amycretin a pill or an injection?
Both forms are being studied: a once-weekly injection and a once-daily tablet. The first phase 3 obesity trial, AMAZE 1, tests the weekly injection.
What are the side effects of amycretin?
Digestive side effects, mostly mild to moderate, were the most common in the trials reported so far. Long-term safety is not yet known.
When will amycretin be available?
No date has been announced. AMAZE 1 is scheduled to finish collecting its main data in 2029, and approval would then require an FDA review.
Peptide Labs does not sell GLP-1 medicines or any prescription drug. This article is general information, not medical advice. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.
Last reviewed October 2026.
Related guides: GLP-1 for Weight Loss: What the Trials Actually Showed, What Is GLP-1? The Hormone, How GLP-1 Drugs Work and Every FDA-Approved Option, Hunger Hormones: How Ghrelin, Leptin and Satiety Signals Work.